Stunning data for Ambit/Astellas AML drug
The promise shown by Ambit Biosciences' quizartinib, which is partnered with Astellas, as a treatment for acute myeloid leukaemia, has caused a stir at the American Society of Hematology meeting in Atlanta. - News - PharmaTimes
by Kevin Grogan in Atlanta
https://www.pharmatimes.com/news/stunning_data_for_ambitastellas_aml_drug_976072